These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20040045)

  • 1. HCV drug discovery aimed at viral eradication.
    Schinazi RF; Bassit L; Gavegnano C
    J Viral Hepat; 2010 Feb; 17(2):77-90. PubMed ID: 20040045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
    Pawlotsky JM
    Antiviral Res; 2003 Jun; 59(1):1-11. PubMed ID: 12834855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Zeuzem S; Nelson DR; Marcellin P
    Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in the antiviral treatment of hepatitis C.
    de Bruijne J; Weegink CJ; Jansen PL; Reesink HW
    Vox Sang; 2009 Jul; 97(1):1-12. PubMed ID: 19392783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus experimental model systems and antiviral drug research.
    Uprichard SL
    Virol Sin; 2010 Aug; 25(4):227-45. PubMed ID: 20960298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir: a new hope in the treatment of chronic hepatitis C?
    Fowell AJ; Nash KL
    Adv Ther; 2010 Aug; 27(8):512-22. PubMed ID: 20652658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.
    Chary A; Holodniy M
    Rev Recent Clin Trials; 2010 Sep; 5(3):158-73. PubMed ID: 20482493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
    Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
    Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin.
    Bhagani S
    Curr Opin HIV AIDS; 2011 Nov; 6(6):483-90. PubMed ID: 22001893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus infection and immunomodulatory therapies.
    Forde KA; Reddy KR
    Clin Liver Dis; 2009 Aug; 13(3):391-401. PubMed ID: 19628156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.